Naclerio Nicholas's Form 4 filing
Alamar Biosciences, Inc. (ALMR) · filed Apr 20, 2026
- Accession no.
- 0001534166-26-000006
- Filed
- Apr 20, 2026, 8:31 PM ET
- Trade date
- Apr 16-20, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 7 derivative transactions. Open-market purchases total $4.00M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Naclerio NicholasCIK 0001534166 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | Class B Common Stock | CConversionAcquired | +4,588,364 | –F1 | – | 4,588,364 | Indirect | |
| Apr 20, 2026 | Class B Common Stock | CConversionAcquired | +922,152 | –F3 | – | 5,510,516 | Indirect | |
| Apr 20, 2026 | Class B Common Stock | JOtherDisposed | −5,510,516 | –F4 | – | 0 | Indirect | |
| Apr 20, 2026 | Common Stock | JOtherAcquired | +5,510,516 | –F4 | – | 5,510,516 | Indirect | |
| Apr 20, 2026 | Common Stock | CConversionAcquired | +346,020 | –F5 | – | 5,856,536 | Indirect | |
| Apr 20, 2026 | Common Stock | CConversionAcquired | +271,782 | –F5 | – | 271,782 | Indirect | |
| Apr 20, 2026 | Common Stock | PPurchaseAcquired | +235,294 | $17.00 | +$3,999,998 | 507,076 | Indirect | |
| Apr 20, 2026 | Common Stock | AGrant or awardAcquired | +5,686 | $0.00 | $0 | 5,686 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | Common Stock | AGrant or awardAcquired | +25,599 | $0.00 | $0 | 25,599 | Direct | |
| Apr 20, 2026 | Class B Common Stock | CConversionDisposed | −1,321,082 | $0.00 | $0 | 0 | Indirect | |
| Apr 20, 2026 | Class B Common Stock | CConversionDisposed | −1,183,832 | $0.00 | $0 | 0 | Indirect | |
| Apr 20, 2026 | Class B Common Stock | CConversionDisposed | −922,152 | $0.00 | $0 | 0 | Indirect | |
| Apr 20, 2026 | Class B Common Stock | CConversionDisposed | −2,083,450 | $0.00 | $0 | 0 | Indirect | |
| Apr 20, 2026 | Common Stock | CConversionDisposed | −346,020 | $0.00 | – | 0 | Indirect | |
| Apr 20, 2026 | Common Stock | CConversionDisposed | −271,782 | $0.00 | – | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock are convertible into shares of Class B Common Stock on a 1:2.418 basis and have no expiration date. The Series A-3 Preferred Stock, Series A-4 Preferred Stock and Series C Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the initial public offering of the Issuer's Common Stock (the "IPO").
Referenced by the price of 1 transaction in Table I.
- F3
The Series B Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.271 basis and has no expiration date. The Series B Preferred Stock automatically converted into shares of Class B Common Stock in connection with the closing of the IPO.
Referenced by the price of 1 transaction in Table I.
- F4
Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
Referenced by the price of 2 transactions in Table I.
- F5
Reflects a convertible note that is convertible into shares of Common Stock of the Issuer. The convertible note has a maturity date of July 8, 2027. The principal amount of the convertible note was automatically converted into shares of Common Stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to the initial public offering price of the Issuer's Common Stock multiplied by 0.85.
Referenced by the price of 2 transactions in Table I.